Please assess the completion status of the following clinical trial:

Trial Title: Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent.~* Over 18 years of age.~* Two consecutive i STAT potassium values, measured 60 (+/- 15) minutes apart, both \>/= 5.1 mmol/L and measured within 1 day before the first dose of ZS on Acute Phase Study Day 1.~* Ability to have repeated blood draws or effective venous catheterization.~* Women of childbearing potential must be using 2 forms of medically acceptable contraception (at least 1 barrier method) and have a negative pregnancy test at Acute Phase Study Day 1. Women who are surgically sterile or those who are postmenopausal for at least 2 years are not considered to be of childbearing potential.~* Controlled diabetic subjects.~Exclusion Criteria:~* Pseudohyperkalemia signs and symptoms, such as hemolyzed blood specimen due to excessive fist clenching to make veins prominent, difficult or traumatic venipuncture, or history of severe leukocytosis or thrombocytosis.~* Subjects treated with lactulose, rifaximin, or other non-absorbed antibiotics for hyperammonemia within 7 days prior to first dose of ZS on Acute Phase Study Day 1.~* Subjects treated with sodium polystyrene sulfonate (SPS; eg, Kayexalate®) or calcium polystyrene sulfonate (eg, Resonium®) within 3 days prior to first dose of ZS on Acute Phase Study Day 1.~* Subjects with a life expectancy of less than 12 months.~* Subjects who are severely physically or mentally incapacitated and who, in the opinion of investigator, are unable to perform the subjects' tasks associated with the protocol.~* Women who are pregnant, lactating, or planning to become pregnant.~* Subjects with diabetic ketoacidosis.~* Presence of any condition which, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated.~* Known hypersensitivity or previous anaphylaxis to ZS or to components thereof.~* Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry.~* Subjects with cardiac arrhythmias that require immediate treatment.~* Subjects on dialysis.~* Subjects randomized into the previous ZS-002, ZS-003, ZS-004, or ZS-004E studies.~* Documented GFR \<15 mL/min within 90 days prior to study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sodium Zirconium Cyclosilicate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).